JAGXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Jaguar Health, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026

$2.82−0.71 (-20.00%)

Close on Oct 19, 2026

Market cap: $2.28M
P/E (TTM): –
Dividend yield: –

Jaguar Health, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Revenue	12	12	9.76	12	4.34	9.39	5.78	4.42	4.36	0.14	0.26	0
Cost of Revenue	3.77	1.96	2.04	2.02	2.33	3.28	3.82	2.77	0.88	0.05	0.12	–
Gross Profit	7.74	9.73	7.72	9.94	2.00	6.11	1.96	1.65	3.48	0.09	0.13	–
Research & Development	25	17	19	18	15	6.41	5.82	5.15	4.27	7.21	6.48	4.22
Selling, General & Admin	28	24	23	27	26	21	20	22	14	6.47	6.10	–
Selling & Marketing	9.24	7.69	6.46	8.84	8.89	6.61	6.94	9.83	3.08	0.49	0.77	–
General & Administrative	19	16	17	18	17	14	14	12	11	5.98	5.34	4.10
Operating Expenses	–	–	–	–	–	–	–	35	39	14	13	8.32
Total Costs & Expenses	57	43	44	46	45	36	35	35	–	–	–	–
Operating Income	-46	-31	-34	-34	-41	-27	-29	-31	-34	-14	-12	-8.32
Interest Expense	0.07	0.23	6.38	13	8.42	2.79	5.73	2.63	1.21	0.99	3.32	0.35
Income from Equity Investments	-0.16	-0.14	-0.05	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	0.04	0.05	0.20	0.95	-0.77	0.19	0.08	0.32	0.09	-0.01	-0.03	–
Asset Impairment Charges	0	0	0	0	0	0	0	5.21	17	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	–	-0.03	–
Legal Settlements	–	–	–	–	–	–	–	1.20	–	–	–	–
Pretax Income	-54	-39	-42	-48	-53	-34	-39	-32	-35	-15	–	–
Income Tax Expense	0	0	0	0	0	0	0.01	–	-13	–	–	–
Net Income incl. Noncontrolling Interests	-54	-39	-42	-48	-53	-34	-39	-32	-22	-15	-16	-8.61
Minority Interest in Earnings	-0.56	-0.76	-0.60	-0.94	-0.01	–	–	–	–	–	–	–
Net Income	-54	-38	-0.04	-0.05	-0.05	-34	-39	-32	-22	-15	-16	-8.61
Preferred Dividends	0.14	0	–	–	–	–	–	–	–	–	–	–
Net Income to Common	-54	-38	-41	-47	-53	-39	–	-32	-22	-15	-17	-9.26
EPS (Basic)(per share)	-22.97	-130.69	-2,678.17	-36.18	-88.22	-3.00	-9.01	-153.27	-531.30	-1,417.50	-2,835.00	-3,402.00
EPS (Diluted)(per share)	-22.97	-130.69	-2,678.17	-36.18	-88.22	-3.00	-9.01	-153.27	-531.30	-1,417.50	-2,835.00	-3,402.00
Shares Outstanding (Basic, Weighted)(shares)	2.33	0.29	0.02	1.31	0.60	13	4.97	0.21	0.04	0.01	0.01	0.00
Shares Outstanding (Diluted, Weighted)(shares)	2.33	0.29	0.02	1.31	0.60	13	4.97	0.21	0.04	0.01	0.01	0.00
EBITDA	-44	-29	-32	-32	-39	-25	-27	-30	-34	-14	-12	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 82.3%
Operating margin: -93.1%
Net margin: -192.6%
Return on equity, FY2025: –

Financial strength

Current ratio: 0.69
Debt to equity: –
Debt to assets: 5.0%
Cash to current liabilities: 14.9%

Valuation

P/E ratio: –
Price to sales: 0.08
Price to book: –
Dividend yield: –